Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Allergan to pay $600 million settle US Botox probe;drops off-label suit

This article was originally published in Scrip

Executive Summary

Officials at the US Department of Justice report that drug maker Allergan has agreed to plead guilty to a single misdemeanour charge and pay $600 million to resolve a years-long federal probe involving allegations of unlawful, off-label promotion of Botox (botulinum toxin A). By settling, the company has disappointed others in the industry, as it also agreed to drop a lawsuit filed against the FDA last year challenging a government rule that prohibited it from disseminating truthful information to physicians to assist them in evaluating risks and benefits of Botox for certain off-label uses. Allergan had wanted a declaration that such rules are unconstitutional, claiming it has a chilling effect on protected speech.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts